Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 1, Issue 12, Pages 986-1001Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd962
Keywords
-
Ask authors/readers for more resources
The discovery of endothelin - a highly potent endogenous vasoconstrictor - in 1988 has led to considerable efforts to develop antagonists of endothelin receptors that could have therapeutic potential in disorders including hypertension, heart failure and renal diseases. However, in general, the results of trials in humans have not mirrored the highly promising effects in animal disease models. Here, we discuss preclinical and clinical results with endothelin antagonists, and consider possible approaches to fully realizing the potential of endothelin antagonism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available